Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients

March 3, 2021 Auto Bot Amgen, Clinical Trials, P-III, Relapsed, reports, results, Studies, Two 0

Shots:

  • The P-III 20120215 study involves assessing of Blincyto vs SoC consolidation CT before alloHSCT in pediatric patients with high-risk first relapsed B-cell ALL. The findings were published in JAMA
  • Results: @median follow-up 22.4mos., patients that are alive and event-free (69% vs 43%); patients achieved MRD negative remission (93% vs 24%); @36mos. OS was (81.1% vs 55.8%)
  • Additionally, the results from the P-III study COG AALL1331 study evaluating Blincyto in children, adolescents and young adults with first-relapse B-ALL, also published in JAMA. In both studies resulted in less severe toxicities and higher rates of MRD remission

Click here ­to­ read full press release/ article | Ref:  PRNewswire | Image: CNBC

The post Amgen Reports Results of Blincyto (blinatumomab) in P-III Study for Relapsed Acute Lymphoblastic Leukemia in Pediatric Patients first appeared on PharmaShots.